Windlas Biotech Ltd

- The transcript does not mention any current or planned new fundraising through debt or equity. - The company has utilized its entire IPO proceeds of INR165 crores effectively as of FY23. - It maintains a healthy liquidity position of INR138 crores as of March 31, 2023. - The company remains committed to disciplined operating cash flow and liquidity management. - No specific comments on raising additional funds via debt or equity were made during the Q&A or management discussion. - The company is capable of funding capacity expansion and growth through internal accruals and existing liquidity.

- Current year capex is planned around INR 20-25 crores initially, with additional space and phased expansion planned for another INR 10-15 crores, totaling approximately INR 40 crores over time. - The INR 40 crores investment is intended to meet capacity needs for the next five years, not just short-term expansion. - Regular annual capex of INR 10-15 crores is expected to manage smaller growth or maintenance needs, including a 10-15% capacity increase via debottlenecking. - Injectable facility capex has increased from earlier estimates of ~INR 50 crores to ~INR 70 crores due to added lyophilized vial lines and new machinery investments for higher speed, longevity, and automation. - Injectable plant mechanical completion expected by September; commercialization expected in Q4 FY24 with revenue starting in FY25. - The company is also actively looking for acquisition/expansion opportunities nearby to meet future growth demands. - All capex and expansion plans are aligned with achieving break-even promptly and supporting sustained growth in all three business verticals (CDMO, Trade Generics, Exports).

- Company is optimistic about future growth across all three verticals: CDMO, Trade Generics & Institutional, and Exports. - CDMO vertical showed 14%-15% YoY growth; management confident of sustaining growth with new customers, products, and capacity expansions. - Trade Generics expected to tap into underserved markets in India's hinterlands with potential for significant growth. - Exports growth is expected but with a gestation period of about 1.5 years; revenues likely to increase from year three onward. - Capacity utilization currently at ~50%; peak utilization for existing CDMO facility is 60-65%, supporting up to INR600 crore revenue. - Planned capex (~INR40 crore phased over years) to meet five-year capacity needs, including injectable facility commercializing from Q4 FY24. - Operating leverage is kicking in with expected 2-3% growth in EBITDA margins over medium term. - Overall, management remains confident in achieving targeted growth sustainably.

- The company is optimistic about future growth across all verticals, targeting sustained upward annual growth despite seasonal variances. - Q1 FY24 EPS grew 29% Y-o-Y to INR5.79; the company intends to continue paying dividends at around 20% of consolidated profits. - EBITDA margins are expected to grow by 2-3% over the medium term (3-4 years) due to operating leverage kicking in. - Operating cash flows have improved significantly in FY23, with a focus on strong cash generation alongside profitability. - The company aims to double CDMO revenues in five years, leveraging increasing regulatory compliance and quality standards favoring established players. - Capex of around INR40 crores planned over next years to support capacity expansion aligned with revenue growth. - New product pipeline and customer base expansion are key drivers for revenue and profit growth. - Overall, confident of consistent improvements in earnings and operating performance while maintaining strong liquidity and shareholder returns.

- CDMO business visibility typically ranges from 1 to 3 quarters: - Multinationals provide 2 to 3 quarters of visibility. - Large Indian corporates give about 1 to 2 quarters. - Smaller customers have less visibility and operate more on lead time basis. - Procurement is done back-to-back against confirmed orders to manage supply chain efficiently. - Business with customers is largely repeat, with continual renewal of 5+ year contracts and no customer lost in over 20 years. - Product portfolio within customers keeps changing, with new product introductions and volume fluctuations occurring regularly. - For exports, there is a gestation period of about 1.5 years from dossier filing to business start. - Overall, the company tracks orders on a near-term basis rather than a multi-year order book.